Education
About Us
Working with TipRanks
Follow Us
TScan Therapeutics (TCRX)
NASDAQ:TCRX
Total Valuation
TScan Therapeutics has a market cap or net worth of $77.53M. The enterprise value is -$9.44M.
Market Cap$77.53M
Enterprise Value-$9.44M
Share Statistics
TScan Therapeutics has 52,314,037 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding52,314,037
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
TScan Therapeutics’s return on equity (ROE) is -0.53 and return on invested capital (ROIC) is -39.68%.
Return on Equity (ROE)-0.53
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-39.68%
Return on Capital Employed (ROCE)-0.40
Revenue Per Employee14.08K
Profits Per Employee-637.50K
Employee Count200
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of TScan Therapeutics is -2.67. TScan Therapeutics’s PEG ratio is 0.14.
PE Ratio-2.67
PS Ratio0.00
PB Ratio0.64
Price to Fair Value1.41
Price to FCF-0.63
Price to Operating Cash Flow-1.38
PEG Ratio0.14
Income Statement
In the last 12 months, TScan Therapeutics had revenue of 2.82M and earned -127.50M in profits. Earnings per share was -1.14.
Revenue2.82M
Gross Profit2.82M
Operating Income-134.82M
Pretax Income-127.50M
Net Income-127.50M
EBITDA-119.74M
Earnings Per Share (EPS)-1.14
Cash Flow
In the last 12 months, operating cash flow was -110.82M and capital expenditures -3.83M, giving a free cash flow of -114.65M billion.
Operating Cash Flow-110.82M
Free Cash Flow-114.65M
Free Cash Flow per Share-2.19
Dividends & Yields
TScan Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.45
52-Week Price Change-85.11%
50-Day Moving Average1.51
200-Day Moving Average3.64
Relative Strength Index (RSI)42.33
Average Volume (3m)449.15K
Important Dates
TScan Therapeutics upcoming earnings date is Aug 13, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateAug 13, 2025
Ex-Dividend Date―
Financial Position
TScan Therapeutics as a current ratio of 8.14, with Debt / Equity ratio of 40.41%
Current Ratio8.14
Quick Ratio8.14
Debt to Market Cap0.11
Net Debt to EBITDA0.68
Interest Coverage Ratio-36.91
Taxes
In the past 12 months, TScan Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
TScan Therapeutics EV to EBITDA ratio is -2.16, with an EV/FCF ratio of -2.26.
EV to Sales92.03
EV to EBITDA-2.16
EV to Free Cash Flow-2.26
EV to Operating Cash Flow-2.34
Balance Sheet
TScan Therapeutics has $290.11M in cash and marketable securities with $97.38M in debt, giving a net cash position of -$192.73M billion.
Cash & Marketable Securities$290.11M
Total Debt$97.38M
Net Cash-$192.73M
Net Cash Per Share-$3.68
Tangible Book Value Per Share$2.15
Margins
Gross margin is -9.41%, with operating margin of -4787.68%, and net profit margin of -4527.66%.
Gross Margin-9.41%
Operating Margin-4787.68%
Pretax Margin-4527.66%
Net Profit Margin-4527.66%
EBITDA Margin-4252.06%
EBIT Margin-4397.94%
Analyst Forecast
The average price target for TScan Therapeutics is $9.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$9.33
Price Target Upside601.50% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast-70.15%
EPS Growth Forecast―